Results 181 to 190 of about 2,108 (191)

Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab

Ophthalmology Retina
Raffaele Raimondi, Michael E Grinton, Tina Felfeli   +2 more
exaly  

Brolucizumab/faricimab

Reactions Weekly
openaire   +1 more source

Faricimab/methotrexate

Reactions Weekly
openaire   +1 more source

Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmology Retina
Bita Momenaei, Taku Wakabayashi, Hana Mansour   +2 more
exaly  

Faricimab/prednisolone

Reactions Weekly
openaire   +1 more source

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial

Japanese Journal of Ophthalmology
Masahiko Shimura
exaly  

Retinal Vasculitis after Intravitreal Faricimab Injection

Ophthalmology Retina
Tang-An Hsiao, Kun-Hsien Li, Chih-Chun Chuang   +2 more
openaire   +2 more sources

Rates of Ocular Adverse Events after Intravitreal Faricimab Injections

Ophthalmology Retina
Bita Momenaei, Taku Wakabayashi, Jason Hsu   +2 more
exaly  

Bevacizumab/faricimab

Reactions Weekly
openaire   +1 more source

Empagliflozin/metformin/faricimab

Reactions Weekly
openaire   +1 more source